WO2009054463A1 - 親油性ｉｌ－２産生抑制物質含有医薬組成物 - Google Patents

親油性ｉｌ－２産生抑制物質含有医薬組成物 Download PDF

Info

Publication number
WO2009054463A1
WO2009054463A1 PCT/JP2008/069250 JP2008069250W WO2009054463A1 WO 2009054463 A1 WO2009054463 A1 WO 2009054463A1 JP 2008069250 W JP2008069250 W JP 2008069250W WO 2009054463 A1 WO2009054463 A1 WO 2009054463A1
Authority
WO
WIPO (PCT)
Prior art keywords
production inhibitor
pharmaceutical composition
composition containing
lipophilic
containing lipophilic
Prior art date
Application number
PCT/JP2008/069250
Other languages
English (en)
French (fr)
Inventor
Takayuki Yoshida
Kiyo Nakanishi
Atsushi Maeda
Kazuhiro Sako
Yuki Kasashima
Hiromu Kondo
Tatsunobu Yoshioka
Yuuki Tsutsui
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to JP2009538258A priority Critical patent/JPWO2009054463A1/ja
Priority to EP08842089A priority patent/EP2206518A4/en
Publication of WO2009054463A1 publication Critical patent/WO2009054463A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

　親油性ＩＬ－２産生抑制物質、および該親油性ＩＬ－２産生抑制物質を経口投与により血中曝露量を抑制しリンパ送達し得る基剤を含有してなる医薬組成物を開示する。前記医薬組成物によれば、親油性ＩＬ－２産生抑制物質の副作用低減のために血中曝露量を抑制し、かつ所望の薬理作用を発現し得る。
PCT/JP2008/069250 2007-10-25 2008-10-23 親油性ｉｌ－２産生抑制物質含有医薬組成物 WO2009054463A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009538258A JPWO2009054463A1 (ja) 2007-10-25 2008-10-23 親油性ｉｌ−２産生抑制物質含有医薬組成物
EP08842089A EP2206518A4 (en) 2007-10-25 2008-10-23 PHARMACEUTICAL COMPOSITION WITH IL-2 PRODUCTION LIPOPHILIC HEMMER

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US98266407P 2007-10-25 2007-10-25
US60/982,664 2007-10-25
US2624408P 2008-02-05 2008-02-05
US61/026,244 2008-02-05
US2929108P 2008-02-15 2008-02-15
US61/029,291 2008-02-15

Publications (1)

Publication Number Publication Date
WO2009054463A1 true WO2009054463A1 (ja) 2009-04-30

Family

ID=40579565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069250 WO2009054463A1 (ja) 2007-10-25 2008-10-23 親油性ｉｌ－２産生抑制物質含有医薬組成物

Country Status (6)

Country Link
US (1) US20090239791A1 (ja)
EP (1) EP2206518A4 (ja)
JP (1) JPWO2009054463A1 (ja)
AR (1) AR070758A1 (ja)
TW (1) TW200932240A (ja)
WO (1) WO2009054463A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011076355A1 (de) * 2011-05-24 2012-11-29 Henkel Ag & Co. Kgaa Lackkoagulation unter Verwendung von Fettsäuren

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108985A (en) 1975-11-04 1978-08-22 Sandoz Ltd. Dihydrocyclosporin c
US4210581A (en) 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
US4220641A (en) 1977-05-10 1980-09-02 Sandoz Ltd. Organic compounds
EP0034567A2 (en) 1980-02-14 1981-08-26 Sandoz Ag A method for the total synthesis of cyclosporins and novel cyclosporins
EP0056782A1 (en) 1981-01-09 1982-07-28 Sandoz Ag Novel cyclosporins
WO1986002080A1 (en) 1984-10-04 1986-04-10 Sandoz Ag Monoclonal antibodies to cyclosporings
JPS61148181A (ja) 1984-12-03 1986-07-05 Fujisawa Pharmaceut Co Ltd Ｆｒ―９００５０６物質およびその製造法
JPS61280435A (ja) 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤
JPS62277321A (ja) 1986-04-02 1987-12-02 Fujisawa Pharmaceut Co Ltd Ｆｒ―９００５０６物質の固形医薬製剤用固溶体組成物
US4786637A (en) 1987-01-30 1988-11-22 Syntex (U.S.A.) Inc. Treatment of allograft rejection with mycophenolic acid morpholinoethylester and derivatives thereof
EP0296122A2 (en) 1987-06-17 1988-12-21 Sandoz Ag Cyclosporins and their use as pharmaceuticals
EP0323042A1 (en) 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
WO1991019495A1 (en) 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
JPH04182429A (ja) 1990-11-15 1992-06-30 Fujisawa Pharmaceut Co Ltd 非水溶液製剤
JPH07138161A (ja) 1993-05-27 1995-05-30 Sandoz Ag ガレヌス製剤
WO1998024418A1 (fr) 1996-12-06 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Compositions medicinales
WO1999049863A1 (fr) 1998-03-26 1999-10-07 Fujisawa Pharmaceutical Co., Ltd. Preparations a liberation prolongee
JP3844491B2 (ja) 1993-10-01 2006-11-15 シンテックス（ユー・エス・エイ）インコーポレイテッド ミコフェノール酸モフェチル高用量経口用懸濁剤
JP2007504102A (ja) * 2003-08-29 2007-03-01 ライフサイクル ファーマ アクティーゼルスカブ タクロリムスを含む改質放出組成物
JP2007517766A (ja) * 2003-09-24 2007-07-05 コンビナトアールエックス インコーポレーティッド 薬物の組み合わせを投与するための治療法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH679119A5 (ja) * 1988-05-13 1991-12-31 Sandoz Ag
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
KR0183449B1 (ko) * 1996-06-19 1999-05-01 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
WO2005105041A2 (en) * 2004-04-27 2005-11-10 Formatech, Inc. Methods of enhancing solubility in water of hydrophobic compounds by micellar dispersions
EP1848407A2 (en) * 2005-02-02 2007-10-31 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108985A (en) 1975-11-04 1978-08-22 Sandoz Ltd. Dihydrocyclosporin c
US4210581A (en) 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
US4220641A (en) 1977-05-10 1980-09-02 Sandoz Ltd. Organic compounds
EP0034567A2 (en) 1980-02-14 1981-08-26 Sandoz Ag A method for the total synthesis of cyclosporins and novel cyclosporins
EP0056782A1 (en) 1981-01-09 1982-07-28 Sandoz Ag Novel cyclosporins
WO1986002080A1 (en) 1984-10-04 1986-04-10 Sandoz Ag Monoclonal antibodies to cyclosporings
JPS61148181A (ja) 1984-12-03 1986-07-05 Fujisawa Pharmaceut Co Ltd Ｆｒ―９００５０６物質およびその製造法
JPS61280435A (ja) 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤
JPS62277321A (ja) 1986-04-02 1987-12-02 Fujisawa Pharmaceut Co Ltd Ｆｒ―９００５０６物質の固形医薬製剤用固溶体組成物
EP0281713B1 (en) 1987-01-30 1991-10-09 Syntex (U.S.A.) Inc. Morpholinoethylester of mycophenolic acid and derivatives thereof, their preparation and use in pharmaceutical compositions
US4786637A (en) 1987-01-30 1988-11-22 Syntex (U.S.A.) Inc. Treatment of allograft rejection with mycophenolic acid morpholinoethylester and derivatives thereof
EP0296122A2 (en) 1987-06-17 1988-12-21 Sandoz Ag Cyclosporins and their use as pharmaceuticals
EP0323042A1 (en) 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
WO1991019495A1 (en) 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
JPH04182429A (ja) 1990-11-15 1992-06-30 Fujisawa Pharmaceut Co Ltd 非水溶液製剤
US6565859B1 (en) 1993-05-27 2003-05-20 Novartis Ag Galenical formulations
US5932243A (en) 1993-05-27 1999-08-03 Novartis Ag Galenical formulations
JPH07138161A (ja) 1993-05-27 1995-05-30 Sandoz Ag ガレヌス製剤
US20030166517A1 (en) 1993-05-27 2003-09-04 Gerd Fricker Galenical formulations
US7025975B2 (en) 1993-05-27 2006-04-11 Novartis Ag Galenical formulations
JP3844491B2 (ja) 1993-10-01 2006-11-15 シンテックス（ユー・エス・エイ）インコーポレイテッド ミコフェノール酸モフェチル高用量経口用懸濁剤
WO1998024418A1 (fr) 1996-12-06 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Compositions medicinales
WO1999049863A1 (fr) 1998-03-26 1999-10-07 Fujisawa Pharmaceutical Co., Ltd. Preparations a liberation prolongee
JP2007504102A (ja) * 2003-08-29 2007-03-01 ライフサイクル ファーマ アクティーゼルスカブ タクロリムスを含む改質放出組成物
JP2007517766A (ja) * 2003-09-24 2007-07-05 コンビナトアールエックス インコーポレーティッド 薬物の組み合わせを投与するための治療法

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
JAPAN OIL CHEMISTS' SOCIETY: "Handbook of Oil Chemistry (Revised 3rd ed", MARUZEN CO.,LTD.
KOBEL ET AL., EUROP.J.APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 14, 1982, pages 273 - 240
PHARMA. RES., vol. 3, no. 1, 1986, pages 48 - 51
See also references of EP2206518A4
TRABER ET AL., HELV.CHIM.ACTA., vol. 60, 1977, pages 1247 - 1255
TRABER ET AL., HELV.CHIM.ACTA., vol. 65, no. 162, 1982, pages 1655 - 1667
TRANSPLANT PROCEEDINGS, 1987, pages 36 - 39
TRANSPLANT PROCEEDINGS, vol. 5, no. 6, 1987, pages 36 - 39
TRANSPLANT, vol. 64, 1997, pages 1695
TRANSPLANTATION, vol. 44, 1987, pages 734 - 738
WARTBURG ET AL., PROGRESS IN ALLERGY, vol. 38, pages 28 - 45
WENGER 1, TRANSP.PROC., vol. 15, no. 1, 1983, pages 2230
WENGER 2, ANGEW.CHEM.INT.ED., vol. 24, 1985, pages 77
WENGER 3, PROGRESS IN THE CHEMISTRY OF ORGANIC NATURAL PRODUCTS, vol. 50, 1986, pages 123

Also Published As

Publication number Publication date
JPWO2009054463A1 (ja) 2011-03-10
US20090239791A1 (en) 2009-09-24
AR070758A1 (es) 2010-05-05
EP2206518A4 (en) 2012-05-09
EP2206518A1 (en) 2010-07-14
TW200932240A (en) 2009-08-01

Similar Documents

Publication Publication Date Title
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
MX2009010289A (es) Composiciones para administracion nasal.
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
ZA200605631B (en) Directly compressible pharmaceutical composition for the oral administration of CCI-779
IL199187A (en) Indole history, pharmaceuticals including them and their use in the manufacture of medicines
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
IL192104A (en) Formulation suitable for subcutaneous administration containing molecules of ctla4ig, sugar and liquid liquid pharmacist acceptable and its use in drug preparation
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
EP2444072A3 (en) Non-mucoadhesive film dosage forms
SG162798A1 (en) Liquid pharmaceutical formulations of docetaxel
RS51688B (en) METHOTREXATE CONCENTRATED SOLUTIONS
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
GB2432314B (en) Topical medicament comprising menthol, camphor, potassium and a source of oxygen
PL2120864T3 (pl) Kompozycja do podawania składników biologicznie czynnych w okolicy narządów płciowych i odbytnicy, i jej zastosowania
WO2007144169A3 (en) Entacapone-derivatives
GB0403406D0 (en) Preparation of carriers for drug delivery and other therapeutic applications
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
JP2007119497A5 (ja)
HK1100352A1 (en) Solid medicament of oral administration and preparation thereof
GEP20115218B (en) Combination drug
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08842089

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009538258

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008842089

Country of ref document: EP